HMGCR and myopathy: For instance, in a study involving a patient with a mutation in HMG-CoA reductase, oral administration of mevalonolactone was found to alleviate symptoms of myopathy (Yogev et al., 2023), indicating its potential as a therapeutic agent for managing statin-related muscle issues.